Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genotyping and longitudinal disease monitoring 1 . However, owing to past emphasis on …

… There was a non-significant trend for stroma-rich tissue samples to have lower tumor …
clustered in the stroma-rich subtype, and shifts to a stroma-rich subtype, were frequent among …

Background Several systemic therapeutic options exist for metastatic castrate-sensitive
prostate cancer (mCSPC). Circulating tumor DNA (ctDNA) can molecularly profile metastatic …

… The retailers are rated using an A–E rating system, from A = excellent to E = poor, and
the NCC then publishes its consumer-focused environmental indicators known as ‘Greening …

Purpose: Targeted agents and immunotherapies promise to transform the treatment of
metastatic bladder cancer, but therapy selection will depend on practical tumor molecular …

… The idiographic nature of a phenomenological approach may be considered as a limitation,
yet this in-depth exploration of participants with similar socio-demographics enables a rich …

Purpose: DNA damage repair (DDR) defects are common across cancer types and can indicate
therapeutic vulnerability. Optimal exploitation of DDR defects in prostate cancer requires …

This research examines the tensions experienced by millennials between their desire to
purchase fast‐fashion and their growing concern for sustainability. The ethical and sustainable …

De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely collected
tissue has hindered genomic stratification and precision oncology. Here, we leveraged a …

Background Activating mutations in AKT1 and PIK3CA are undercharacterised in metastatic
castration-resistant prostate cancer (mCRPC), but are linked to activation of …